Publication dates

All regions

Rheumatoid Arthritis Industry, December 2014 Market Reports from Top Publishers

You might be interested in: Medical Equipment, Therapeutics, Disease Testing, more »


 
1-20 of about 8 900 reports for Rheumatoid Arthritis

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • December 2014
  • by Global Data

... And age groups that present the best opportunities for ra therapeutics in each of the markets covered. Epicast report: rheumatoid arthritis - epidemiology forecast to 2023 1 table of contents2 ...

Daiichi Sankyo Company, Limited - Product Pipeline Review - 2014

Daiichi Sankyo Company, Limited - Product Pipeline Review - 2014

  • $ 1 500
  • Industry report
  • November 2014
  • by Global Markets Direct

... Disorders 87small molecule to agonize ppar gamma receptor for type 2 diabetes 88small molecule to inhibit i-kappab kinase beta for rheumatoid arthritis 89small molecule to inhibit pde4 for copd 90 ...

Amgen, Inc. - Strategy and SWOT Report

Amgen, Inc. - Strategy and SWOT Report

  • $ 175
  • Company report
  • November 2014
  • by MarketLine

... Of cancer, kidney disease, rheumatoid arthritis and other serious illnesses. It primarily operates in the us where it is headquartered in thousand oaks, california. Amgen employed about 20,000 people ...

Vascular Biogenics Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Vascular Biogenics Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2014
  • by Global Data

... Inflammatory agents. Vb-201 is an oral disease modifying medicine for the treatment of chronic immuno-inflammatory diseases such as psoriasis, inflammatory bowel disease, multiple sclerosis rheumatoid arthritis ...

IMMCO Diagnostics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

IMMCO Diagnostics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2014
  • by Global Data

... Instruments and immuglo autoantibody atlas. Immco's lab services include tests for thyroiditis, rheumatoid arthritis, type 1 diabetes, celiac disease, ulcerative colitis, crohn's disease, systemic lupus ...

Astralis, Ltd. SWOT Analysis, Strategy, Revenues and Profits

Astralis, Ltd. SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Dermatitis, skin papillomas, and rheumatoid arthritis. It's biologic products technology platform is used for the development of products. The company's initial product cand is psoraxine which is used ...

Herborium Group, Inc. (HBRM) - Financial and Strategic SWOT Analysis Review

Herborium Group, Inc. (HBRM) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Infectious formula with anti mersa capabilities, rheumatoid arthritis, refractory tumors and diabetes products. The company offers treatment in the therapeutic areas, such as dermatology, sexual health and performance ...

MetrioPharm AG (Symbol:MP5) SWOT Analysis, Strategy, Revenues and Profits

MetrioPharm AG (Symbol:MP5) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Inflammatory and anti-infective properties. Its mp1032 is used in the treatment of rheumatoid arthritis, inflammatory bowel disease, copd, local and generalized bacterial infections and viral infections. Metrio ...

Microbio Co., Ltd. (Symbol:4128) SWOT Analysis, Strategy, Revenues and Profits

Microbio Co., Ltd. (Symbol:4128) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... Such as fatigue and appetite loss, anemia, colorectal cancer, liver cancer, rheumatoid arthritis and hepatitis c, among others. The company has collaboration with multinational pharmaceutical or biotech companies ...

Conpharm AB (CONP B) - Financial and Strategic SWOT Analysis Review

Conpharm AB (CONP B) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

... On substances extracted from the podophyllum plant worldwide. Its sectors include podophyllum emodi, wartec and condyloma, and reumacon and rheumatoid arthritis. Conpharm's product wartec is used ...

About 1 200 reports for Rheumatoid Arthritis

Download Unlimited Documents from Trusted Public Sources

Astellas Annual Report 2013

  • January 2013
    142 pages
  • Drug  

  • Japan  

    World  

    Asia  

View report >

2 Companies for Rheumatoid Arthritis

Read our Company Profiles

Johnson and Johnson

United States

Amgen Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.